ADPT President and COO Julie Rubinstein Sells $303K of Stock

Julie Rubinstein, President and COO of Adaptive Biotechnologies Corporation (NasdaqGS: ADPT), sold 11,881 shares on October 12, 2026. The sale was valued at approximately $303,127.08 at a price of $25.51 per share. This transaction was planned, indicating it was likely part of a strategy rather than a reaction to market conditions.

Inside Julie Rubinstein's Trade

Rubinstein's sale comes as Adaptive Biotechnologies' stock trades below its 50-day moving average, which is currently at $26.17. The recent trading price of $24.19, as of October 16, 2026, is about 7.5% lower than this average. The stock also sits well above its 52-week low of $12.00, but is 21.3% below its 52-week high of $30.74.

Other Institutional Activity in Adaptive Biotechnologies

Vanguard Capital Management LLC increased its stake in Adaptive Biotechnologies by 309,576 shares, bringing its total to 6,403,587 shares valued at about $153.8 million. Wellington Management Group, LLP also grew its holdings significantly, adding 2,054,031 shares for a total of 5,911,366 shares worth approximately $142.0 million. Blackrock Inc. raised its position by 1,835,856 shares, totaling 15,139,159 shares valued at about $363.6 million. Meanwhile, Viking Global Investors, L.P. maintained its position with no change, holding 29,993,708 shares valued at about $720.4 million.

Adaptive Biotechnologies Corporation Stock Down 5.4%

As of October 16, 2026, Adaptive Biotechnologies shares are trading around $24.19. This price is below the company's 50-day moving average and 18.9% lower than the mean price target of $29.81 set by analysts. The stock's current position may reflect investor caution as they await the next earnings report scheduled for November 4, 2026.

Recent Earnings

For the trailing twelve months, Adaptive Biotechnologies reported revenue of approximately $308.1 million, showing a year-over-year growth of 21.5%. However, the company has not been profitable, with a negative net margin of 20.7% and an EPS of -0.41.

Insider Buying and Selling at Adaptive Biotechnologies Corporation

Earlier this year, other insiders at Adaptive Biotechnologies also engaged in significant trades. Sharon Benzeno, Chief Commercial Officer, sold 11,034 shares on June 26, 2026, for about $231,714, while on June 29, 2026, she purchased over 103,000 shares valued at around $751,605. These transactions, alongside Rubinstein's recent sale, highlight ongoing insider activity at the company.

Analysts Set New Price Targets

On September 29, 2026, Goldman Sachs initiated coverage of Adaptive Biotechnologies with a 'Buy' rating and a target price of $35.00. This follows other analysts maintaining their ratings, including BTIG, which rated the stock as 'Buy' with a target of $34.00 on September 22, 2026. The consensus rating for the stock remains 'strong buy' with an average price target of $29.81 based on eight analyst opinions.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation develops technologies to diagnose and treat various diseases using its immune medicine platform. The company focuses on immunosequencing to create clinical data that helps decode the adaptive immune system. With a market cap of about $3.83 billion, the company continues to innovate in the healthcare sector.

Bottom Line

Investors will be looking closely at Adaptive Biotechnologies as it approaches its next earnings date on November 4, 2026. With mixed signals from analysts and significant insider trading activity, the stock's performance will be pivotal in the upcoming weeks.